CRP and lung cancer: However, more recently, the increased application of high-sensitivity CRP detection assays and lower cut-offs (usually around 0.3 mg/dL) within a “high-sensitivity” GPS has been shown to significantly improve patient risk stratification in a number of studies, e.g., on gastric cancer, lung cancer, and hepatocellular carcinoma [30,34,35,36].